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Summary
One goal of aging research is to find drugs that delay the onset of
age-associated disease. Studies in invertebrates, particularly
Caenorhabditis elegans, have uncovered numerous genes
involved in aging, many conserved in mammals. However, which
of these encode proteins suitable for drug targeting is unknown.
To investigate this question, we screened a library of compounds
with known mammalian pharmacology for compounds that
increase C. elegans lifespan. We identified 60 compounds that
increase longevity in C. elegans, 33 of which also increased
resistance to oxidative stress. Many of these compounds are
drugs approved for human use. Enhanced resistance to oxidative
stress was associated primarily with compounds that target
receptors for biogenic amines, such as dopamine or serotonin. A
pharmacological network constructed with these data reveal that
lifespan extension and increased stress resistance cluster
together in a few pharmacological classes, most involved in
intercellular signaling. These studies identify compounds that can
now be explored for beneficial effects on aging in mammals, as
well as tools that can be used to further investigate the
mechanisms underlying aging in C. elegans.
Key words: aging; dopamine; drugs; oxidative stress; phar-
maceutical; serotonin.
Introduction
Studies of the short-lived nematode, Caenorhabditis elegans, have
uncovered numerous genes involved in aging, some of which cluster in
specific biochemical pathways (Donmez & Guarente, 2010; Kenyon,
2010). It has become increasingly evident that at least some mechanisms
that underlie aging in C. elegans, and fruit flies are evolutionarily
conserved in mammals. For example, dietary restriction (DR) can increase
lifespan in multiple organisms ranging from yeast to mammals and
decreased signaling through the insulin/insulin-like growth factor (IGF)
signaling pathway can increase lifespan not only in C. elegans, but also
in mice (Holzenberger et al., 2003; Harrison et al., 2009).
Can interventions that increase longevity also delay the onset of
age-associated disease? Several observations are indeed consistent with
this idea. DR, reduced insulin/IGF signaling, and decreased TOR (target
of rapamycin) signaling are all reported to delay the onset, or improve
the outcome, of certain age-related diseases, such as cancer or
neurodegenerative disease in C. elegans and mouse models of these
diseases (Hursting et al., 1994; Pinkston et al., 2006; Raffaghello et al.,
2008; Cohen et al., 2009; Rangaraju et al., 2009; Johnson et al., 2013).
What strategies are most likely to lead to drugs for combating the
deleterious effects of aging in humans? The ability of small molecules
to extend lifespan has now been amply demonstrated in invertebrates
(Kang et al., 2002; Evason et al., 2005; Wilson et al., 2006; Petras-
check et al., 2007; McColl et al., 2008; Srivastava et al., 2008; Pietsch
et al., 2009; Onken & Driscoll, 2010; Alavez et al., 2011) and also
confirmed in mice by the finding that lifespan can be increased by
rapamycin, an immunosuppressant that blocks TOR activity (Harrison
et al., 2009).
To identify additional drugs that would delay aging, but not have
other undesirable effects, one could begin by using a ‘reverse pharma-
cology’ approach in which one would screen for compounds that target
proteins implicated in aging and then test those compounds for effects
on aging.
Alternatively, one could use a ‘forward pharmacology’ approach in
which compounds would be directly screened in vivo for their ability to
delay aging or age-associated phenotypes. However, aging and lifespan
are ‘whole organism’ phenotypes that would make in vivo screens in
mammals time-consuming and prohibitively expensive.
Given the apparent evolutionary conservation of aging mechanisms,
we reasoned that it might be possible to circumvent these problems by
first screening for compounds that increase the lifespan of a short-lived
invertebrate and then testing the identified compounds for beneficial
effects in mammals. By screening compounds with known mammalian
targets, many with established safety profiles, for those that extend
the lifespan of C. elegans, it may be possible to hasten the
identification of compounds with similar effects in mammals. In this
context, rapamycin provides a proof of principle as it extends lifespan
in invertebrates as well as in mammals (Harrison et al., 2009; Robida-
Stubbs et al., 2012).
As a first step in this direction, we screened for compounds that
increase C. elegans longevity using a library of 1280 compounds with
known or suspected mammalian targets, many approved for use as
drugs in humans. These studies identified 60 compounds that increased
C. elegans lifespan. These compounds act on a variety of mammalian
proteins, suggesting the potential involvement of homologous nema-
tode proteins in aging. Interestingly, similar to some genetic alterations
that increase C. elegans longevity, 33 of the compounds also increased
the animal’s resistance to oxidative stress.
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Results
A large-scale screen for compounds that increase C. elegans
lifespan
To search for compounds that increase lifespan when given to adult
C. elegans, we screened a commercial collection of pharmacological
agents with known or suspected targets in humans. This collection,
called Library of Pharmacologically Active Compounds (LOPAC), contains
1280 different compounds that are grouped into pharmacological
classes according to their mammalian targets (Fig. 1d, Experimental
Procedures). Many of the compounds in the LOPAC library are in current
use as pharmaceutical agents in humans.
To screen the LOPAC library for compounds that increase C. elegans
lifespan, we used methods similar to those we employed in a previous
screen of 88 000 small molecules of undefined function (Petrascheck
et al., 2007, 2009; Solis & Petrascheck, 2011). Animals were grown in
liquid medium at 20 °C in 96-well plates with 5–15 animals per well.
Beginning at day 1 of adulthood, animals in each well were exposed
continuously to a single compound or to the vehicle control (0.33%
DMSO). Each compound was tested at a concentration of 33 lM on an
average population of 41  7 animals. The fraction of live animals per
well was monitored until 98.1% was no longer alive (59 783 of 60 921
animals). The mean lifespan of animals treated with the vehicle control
was 21.1  0.7 days, well in agreement with the literature (Kenyon,
2010).
In the 1280 compounds screened, we obtained 156 primary hits using
both the Cox-proportional hazard model and the Mantel–Haenzel
version of the log-rank test (Fig 1a, Table S1). We leveraged a two stage-
procedure, whereby we intentionally chose ‘soft’ statistical criteria for
primary hits with a false discovery rate (FDR) of 0.66 (Storey & Tibshirani,
2003). This was performed to maximize the identification of true positive
hits, but at the expense of including a large number of false positives,
which could later be removed in a secondary screen.
Standard quality control measures for high-throughput assays, such
as the Z’ factor (Zhang et al., 1999), are inadequate for lifespan screens
because survival data are not normally distributed (Fig. S5–S7 Supple-
mentary Methods). Instead, we assessed the quality of the screen by
three different methods. First, we estimated the uniformity of the DMSO
controls and the possible number of hits by generating a Q-Q plot that
graphs expected versus observed P values (Fig. 1b). In Q-Q plots, P values
due to chance will follow a 45º line (dashed line) as was observed for the
DMSO-treated control populations (n = 250 control populations). This
confirmed the uniformity of the screening conditions. In contrast, the P
values for compound-treated populations very strongly deviated from
the 45º line suggesting that a large number of compounds affected
lifespan.
Second, we estimated the ability of the screen to detect any given
percent increase in lifespan. This was performed by generating a
parametric survival time model based on the Gompertz equation using
the DMSO-treated control population as input data. This model allowed
us to simulate the screen in silico (Johnson, 1990) (Fig. S1c). As a test, we
conducted a reference screen in which we evaluated 122 populations of
animals treated with vehicle alone and six populations treated with
mianserin, a compound that extends lifespan by 31% (Petrascheck
et al., 2007, 2009; Yu et al., 2010). All six mianserin-treated populations
were identified as hits, as two populations were treated with vehicle
alone (false positives). This empirical detection rate was consistent with
the survival time model-derived detection rate of 99% for mianserin
(Fig. 1c).
Third, we examined library compounds previously reported to extend
nematode lifespan at the concentration and temperature used in our
screen. We determined that the hits obtained in the primary screen
included all four such compounds: mianserin, cyproheptadine, methio-
thepin, and pregnenolone (Broue et al., 2007; Petrascheck et al., 2007).
A fifth compound, doxycycline, reported to extend lifespan subsequent
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Fig. 1 Overview of screening strategy and results. (a) Schematic shows screening
strategy and results, with numbers of compounds in parentheses. (b) Q-Q plot
showing lifespan P value-distribution for animals treated with DMSO (black) or
compounds (red). Dashed line shows expected P value distribution due to chance.
(c) In silico modeling of control data shows the probability of detecting a given
increase in lifespan using the numbers of animals employed in the screen (n)
(average, 41 (red line); range in >90% of experiments, 30–58). (d) Pie charts show
the fraction of compounds belonging to different pharmacological classes in the
Pharmacologically Active Compounds (LOPAC) library (Library) and among
compounds that increased lifespan (Hits).
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to these analyses, also belonged to the selected hits (Houtkooper et al.,
2013). In addition, another compound that was represented twice in the
library was found to extend lifespan in both instances. Taken together,
these tests confirmed the high quality of the screening data.
We next conducted secondary screen on 153 of the 156 primary hits,
excluding three compounds previously found to increase lifespan, but
keeping a fourth (mianserin) as a positive control. Due to the high FDR,
we used in the primary screen (0.66), we expected roughly 100 false
positives among the primary hits. We first retested the 59 weakest
primary hits at 33 lM, and the concentration used in the primary screen.
Of these weaker primary hits, 54 were false positives, with only five
compounds showing a positive effect on lifespan. We then tested these
five compounds and the remaining 94 stronger primary hits at five
different concentrations ranging from 3 to 176 lM, using 30–99 animals
for each concentration (Fig. S3). A compound was considered a
secondary hit if it produced a significant increase in lifespan at two
consecutive concentrations. Exceptions were made for two compounds
(nicardipine and BRL15572) that extended lifespan at only a single
concentration, but did so with a P value of <105. Compounds identified
as secondary hits were each tested on a minimum of 128 animals, with
an average of 245 animals tested per compound (Table S2).
The LOPAC library contains 28 antibiotics, three of which increased
C. elegans lifespan (by 16–29%; Table 1). Although one of these
three tetracycline antibiotics, minocycline, has annotated mammalian
targets, this effect could be caused by killing or by preventing growth
of the bacteria used for food, as feeding C. elegans with dead, or
nonproliferating bacteria can increase lifespan (Gems & Riddle, 2000;
Garigan et al., 2002; Cabreiro et al., 2013). To test whether these
three antibiotics are the only lifespan-extending compounds with
antibiotic activity, we measured the effect of each compound on the
growth of the bacterial strain used in the screen (OP50) at a
concentration 1.5-fold higher than the optimal concentration used in
the lifespan assay. Bacterial growth was inhibited by all three
antibiotics, as well as by the dopamine receptor agonist N-(2-[4-(4-
Chlorophenyl) -b -piperazin- 1-yl]ethyl)-3-methoxybenzamide and the
nitric oxide donor 4-Phenyl-3-furoxancarbonitrile. Lifespan extension by
these five compounds could therefore be due to their effects on the
feeding bacteria. The other 52 compounds that increased lifespan had
no detectable effect on bacterial growth (Fig. S4). We decided to
include all compounds in further analysis, however, because doxycy-
cline was shown recently to increase lifespan in animals fed with
tetracycline-resistant bacteria and minocycline was found to increase
lifespan in Drosophila melanogaster (Oxenkrug et al., 2012; Houtko-
oper et al., 2013), suggesting antibiotic-independent mechanisms for
both compounds.
These experiments identified 57 compounds (including mianserin) as
secondary hits that produced a statistically significant increase in
C. elegans lifespan. Five of these compounds could increase lifespan
via their direct effects on nematodes or indirect effects resulting from the
inhibition of growth of the feeding bacteria. Four compounds extended
lifespan by an average of 1–9%, 24 by 10–19%, 13 by 20–29%, 14 by
30–39% and 2 by 40% or more (Fig. 2). Of the 57 compounds, nearly
half (27/57) have been approved for use as pharmaceutical drugs in
humans (Table 1, Fig. S2).
Lifespan extending compounds cluster in certain
pharmacological classes
The 1280 compounds in the LOPAC library are grouped into 55 different
pharmacological classes based on their protein targets in mammals
(humans/mice). The 57 compounds that increased C. elegans lifespan
belong to 15 of those classes (Fig. 1d). The presence of numerous
proteins with related sequences and functions in C. elegans and
mammals suggests that many of the identified compounds might
interact with homologous proteins in humans and nematodes. Consis-
tent with this idea, several compounds that interact with human proteins
have previously been shown to interact with a homologous C. elegans
protein with a related function (Kwok et al., 2006; Petrascheck et al.,
2007).
Notably, a large percentage (51/57, 89%) of the compounds that
increased C. elegans lifespan in these studies target mammalian proteins
involved in intercellular signaling. Four library classes with compounds
that increased nematode longevity contain drugs that target mammalian
biogenic amine receptors. These receptors are G protein-coupled
receptors (GPCRs) that recognize adrenaline/noradrenaline, dopamine,
histamine, or serotonin. The biogenic amine receptors are closely related
to one another and many of the compounds that act on one type also
have activity on another (Table 1). Many of the compounds that act on
these receptors are also related in structure (Fig. S1). Most of the
compounds from these classes that increased C. elegans lifespan are
antagonists for their mammalian target receptors. The maximum
increase in lifespan seen with these compounds was 43% (Table 1,
Table S2). C. elegans has receptors homologous to mammalian biogenic
amine receptors that recognize serotonin, dopamine, tyramine, or
octopamine, though histamine receptors have not been identified thus
far. Moreover, previous studies indicate that mianserin increases
nematode lifespan by inhibiting two different nematode biogenic amine
receptors and that animals mutant for a different nematode receptor of
this class show increased longevity (Murakami & Murakami, 2007;
Petrascheck et al., 2007).
Three other compound classes that increased nematode lifespan have
functions related to those of the biogenic amine receptors. Compounds
identified in two of these classes, the cholinergic and glutamate classes,
act on GPCRs that are activated by acetylcholine (muscarinic acetylcho-
line receptors) or glutamate (metabotropic glutamate receptor, Grm7).
Compounds acting on these receptors increased C. elegans lifespan by
15% and 8%, respectively. A third class related to the biogenic amine
class is the ‘cyclic nucleotide’ class. The three members of this class that
increased C. elegans lifespan (by 15–27%) are all inhibitors of human
cyclic nucleotide phosphodiesterases (PDEs). PDEs are linked to GPCR
signaling in that they degrade cAMP or cGMP generated by signaling
through some GPCRs.
Two additional classes of compounds that target proteins involved in
transmembrane signaling are those that act on ion channels. In addition
to one member of the glutamate class that acts on a glutamate-gated
ion channel [the NMDA receptor (+16% lifespan increase)], targets of
these compounds include calcium (25% maximum lifespan increase) and
potassium channels (42% maximum lifespan increase).
Other compounds that increased C. elegans lifespan include those
that target mammalian serine proteases (+13%), tubulin (+12%),
nuclear hormone receptors (+7–23%), a nitric oxide donor (+30%),
and cytoplasmic protein kinases or receptor tyrosine kinases (+5–27%).
Three tetracycline-type antibiotics also increased lifespan (+16–29%),
but could do so indirectly by killing feeding bacteria, as noted above.
These results demonstrate that C. elegans lifespan can be extended
by numerous compounds that target a large variety of different
mammalian proteins. C. elegans has proteins homologous to many,
and possibly most of the annotated targets of these compounds. While
those homologs are the most likely targets of the identified compounds
in the nematode, future studies will be needed to ascertain whether the
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Table 1 Name, pharmacology and effects of the 57 hit compounds
Class Compound/drug Targeta Actionb
Lifespan
increasec (%)
OSR
changed (%)
Antibiotic Demeclocycline hydrochloride* Bacterial 30S subunit  16 37***
Doxycycline hydrochloride* Bacterial 30S subunit  18 51***
Minocycline hydrochloride* Bacterial 30S subunit (mammals: MMP9,
VEGF, ALOX5, Cytochr. C, IL1B, CASP-1, CASP-3)
 29 39***
Biochemistry 3,4-Dichloroisocoumarin Serine proteases  13 30***
Biogenic amine/adrenoceptor Amoxapine* SLC6A2 (HTR 2A, 2C, 6, 7; DRD2; SLC6A4)  33 97***
Doxazosin mesylate* ADRA1A (ADRA 1B, 1D, 1C)  15 4
Guanabenz acetate* ADRA2A + 12 29***
Guanfacine hydrochloride* ADRA2A + 15 27
Naftopidil dihydrochloride ADRA1A  14 31***
Nortriptyline hydrochloride* SLC6A2 (ALB; SLC6 A2, A4; HTR 2A, 2C, 6;
ADRA1A; CHRM1, M2, M3, M4, M5; HRH1)
 21 63***
Biogenic amine/dopamine ()-Octoclothepin maleate DRD2 (DRD1, 3, 4; HTR 2A, 6, 7)  38 108***
BTCP hydrochloride SLC6A3  14 23
Chlorprothixene hydrochloride* DRD2 (HTR 2A, 2B, 2C, 6, 7; DRD3, 4;
CHRM1, M2, M3, M4, M5; HRH1)
 33 91***
cis-(Z)-Flupenthixol dihydrochloride* DRD1 (DRD2, D4, D5; ABCB1;
HTR 2A, 2C; ADRA1A, HRH1)
 30 92***
Cortexolone maleate DRD2 (precurser of cortisol synthesis)  11 17
Dihydroergocristine methanesulfonate DRD2 (ADRA1A, HTR-receptors)  34 74***
Loxapine succinate* DRD2 (DRD1, D3, D4, D5; HTR 2A, 2C, 6, 7;
ADRA1A, 1B, 2A, 2B, 2C; CHRM1, M3; HRH1)
 43 99***
Methylergonovine maleate* DRD1 (HTR 1E, 1F, 2A, 2B, 2C, 7)  28 106***
N-(2-[4-(4-Chlorophenyl)piperazin-
1-yl]ethyl)-3-methoxybenzamide
DRD4 + 35 101***
Pergolide methanesulfonate* DRD1, DRD2 (DRD3, D4, D5; HTR 1A, 1D,
2A, 2B, 6, 7; ADRA 2A, 2B, 2C; HRH1)
+ 37 97***
Propionylpromazine hydrochloride DRD2  20 78***
Thioridazine hydrochloride* DRD1, DRD2 (DRD3, D4; HTR 1A, 1B, 2A,
2C, 6, 7; ADRA 1A, 1B, 2A, 2C;
CHRM1, M2, M3, M4, M5; HRH1)
 31 28***
Biogenic amine/histamine Loratadine* HRH1  18 41***
Oxatomide HRH1  25 71***
Promethazine hydrochloride* HRH1 (CHRM1, M5; DRD2; HTR2A, ADRA1A)  32 81***
Biogenic amine/serotonin PAPP/LY-165,163 HTR1A (HTR1D, DRD2)  33 83***
Amperozide hydrochloride HTR2A (HTR6, ADRA1A, DRD2)  38 60***
BRL 15572 HTR1D (HTR 1A, 1B, 2A, 2B)  10 15
Dihydroergotamine
methanesulfonate*
HTR1D (ADR2A, HTR2B) + 24 69***
Ketanserin tartrate HTR2A (HTR2C, ADRA1A)  13 40***
LY-367,265 HTR2A (SLC6A4)  34 83***
Metergoline HTR2A (HTR1B, 1A, 2C, 6, 7)  23 65***
Mianserin hydrochloride* HTR2A (HTR 1A, 1D, 2A, 2B, 2C, 3, 6, 7;
ADRA 2A, 2B, 2C; HRH1; OPRK1)
 32 77***
Ca2+ Channel Cinnarizine* CACNA1A (HRH1, DRD2, HRH4)  15 8
Nicardipine hydrochloride* CACNA1C (ABCB1, ABCG2)  23 16
Nitrendipine* CACNG1 (ABCG2)  25 39***
Cholinergic Hexahydro-sila-difenidol
hydrochloride
CHRM3 (CHRM1, M2)  15 22
Cyclic Nucleotide BRL 50481 PDE7  18 1
Trequinsin hydrochloride PDE3  27 64***
Vinpocetine PDEI  15 3
Cytoskeleton and ECM Vincristine sulfate* TUBB2A  12 13
Glutamate AMN082 Grm7 + 8 18
Eliprodil NMDA  16 51***
Hormone (R,R)-cis-Diethyl tetrahydro-2,
8-chrysenediol
ESR2, ESR1  7 1
Beta-Estradiol* ESR1, ESR2, SHBG, NR1I2 + 7 12
Cyproterone acetate* AR  23 7
Danazol* ESR1 (GNRHR, R2; SHBG, CCL2) + 13 2
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homologs are involved in the observed effects of the compounds on
nematode lifespan. As many of the possible C. elegans targets have not
previously been linked to aging, such studies could potentially provide
additional information as to the mechanisms underlying aging in the
animal.
Many of the compounds identified in these studies act on multiple
mammalian proteins and could actually belong to several pharmacolog-
ical classes. To gain further insight into interrelationships among the
compounds found to increase lifespan, we generated a pharmacological
network (Fig. 5) (Smoot et al., 2011). The network incorporates
compound-target interaction data based on LOPAC library annotations,
DrugBank, and the PDSP-binding database (Table 1) (Roth et al., 2000;
Knox et al., 2011). This approach generated a network consisting of 139
nodes (57 compounds and 82 protein targets) with three main network
clusters centered around hormone-signaling, tetracycline antibiotics and
biogenic amine signaling.
The pharmacological network clusters all the biogenic amine target-
ing compounds into one network component through common receptor
targets. The most highly targeted receptors are the dopamine receptor
DRD2 and the serotonin receptor HTR2A. It further connects calcium
channel blockers to the biogenic amine network through binding of
HRH1 and DRD2. Compounds targeting hormone signaling form a
cluster that is distinct from biogenic amine signaling and that contains
three of the four compounds that affect hormone signaling, all
connected by common targets.
Even though no structural information went into the generation of
this network, it clusters many structurally similar compounds through
their common targets. Alkaloids like methylergonovine and metergoline,
belong to different pharmacological classes, but are structurally related
(Fig. S1) and are connected through the binding to HTR2A, HTR2C, and
HTR7 serotonin receptors (Fig. 5). Similarly, the calcium channel blocker
cinnarizine is connected to the antihistamine oxatomide through binding
to HRH1. Despite their different classification, these two compounds
share structural similarities. In addition, all components in the hormone
signaling network are structurally related. Over all, structurally similar
compounds tend to cluster together in the pharmacological network.
Lifespan-extending compounds that protect C. elegans from
oxidative stress
Decreases in the ability to respond to different forms of stress have been
proposed to play an important role in aging and susceptibility to age-
associated diseases. Consistent with this idea, long-lived C. elegans
mutants in the insulin/IGF-signaling pathway show increased resistance
to oxidative stress as do long-lived nematodes subjected to RNAi
targeting the electron transport chain (Honda & Honda, 1999; Lee et al.,
2006), though other interventions that increase longevity do not affect
stress resistance. While increased oxidative stress resistance alone is
unlikely to be sufficient to increase longevity, it may be associated with
an array of changes that together increase lifespan in certain settings
(Gems & Doonan, 2009; Van Raamsdonk & Hekimi, 2009; Yang &
Hekimi, 2010; Shore et al., 2012).
To examine whether any of the 57 compounds that increased lifespan
can influence the response of C. elegans to oxidative stress, we tested
the effects of these compounds on animals exposed to paraquat, a
generator of radical oxygen species (ROS) (Fukushima et al., 2002).
Starting from day 1 of adulthood, animals were treated with a single
compound for five days and then paraquat was added to a final
concentration of 100 mM. The fraction of live animals per well was
measured 24 h later.
Of the 57 compounds tested, 33 (57.9%; P < 0.005, FDR 0.015)
caused a significant increase in the survival of animals exposed to
paraquat, 21 had no effect, and three reduced resistance to oxidative
stress. Of the control animals that received vehicle alone (0.33% DMSO),
39.8% were alive following paraquat treatment. In contrast, in the
presence of the 33 compounds with a significant effect, the percentage
of live animals ranged from 50.6% to 83%, corresponding to increases
in stress resistance of 27% to 108%, respectively (Fig. 3).
The 33 compounds that increased C. elegans resistance to oxidative
stress belong to nine of the 15 pharmacological classes that contained
lifespan-extending compounds. Compounds that increased stress resis-
tance included those that target the following mammalian proteins: all
four classes of biogenic amine receptors, a phosphodiesterase, the NMDA
Table 1 Continued
Class Compound/drug Targeta Actionb
Lifespan
increasec (%)
OSR
changed (%)
K+ Channel Psora-4 Kv1.3  42 22
Quinidine sulfate* KCNK1 (KCNH2, KCNK6, SCN5A, CHRM2)  12 15
Nitric Oxide 4-Phenyl-3-furoxancarbonitrile Nitric oxide donor N/A 30 4
Phosphorylation 7-Cyclopentyl-5-(4-phenoxy)phenyl-
7H-pyrrolo[2,3-d]pyrimidin-4-ylamine
lck  11 8
Cyclosporin A* CAML (PPIA, ABCB1, PPP3R2)  18 43***
DAPH EGFR  15 43***
Kenpaullone CDK1 (CDK2, CDK5, GSK3)  27 31***
LFM-A13 BTK  27 60***
SU 4312 VEGEFR, PDGFR  5 27***
Tyrphostin AG 1478 EGFR  11 21
*Compounds/Drugs approved for human use.
***P < 0.005 for the observed change in stress resistance.
aTarget information was obtained using the LOPAC annotation from Sigma and information from DrugBank and the PDSP database; Sigma annotations were used for
primary target classifications.
bDescribes whether the compound has an activating (+) or inhibiting () effect on the target. Some compounds show different actions on different targets.
cDescribes% increase in lifespan relative to DMSO-treated animals; average of three to six independent experiments using the optimal concentration of compound.
dDescribes% change in survival under conditions of oxidative stress relative to DMSO-treated animals, (C. elegans); mean of four experiments shown.
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ionotropic glutamate receptor, a protease inhibitor, calcium channel
blockers, antibiotics, and a receptor tyrosine kinase. The greatest effects
were seen with three compounds that target mammalian dopamine
receptors (80–83%of animals alive). The lowest protection was seen with
a compound (SU4312) that acts on the mammalian VEGF receptor
(50.6% alive). By choosing an FDR of 0.015, we expect less than one false
positive among those 33 compounds. Twenty-one compounds did not
increase oxidative stress resistance, however, and three compounds
(LFM-A13, kenpaullone and minocycline) significantly decreased oxida-
tive stress resistance. Thus, like some other interventions that increase
lifespan, some compounds that increase lifespan also increase resistance
to oxidative stress, whereas others do not.
Analyzing the relationship between lifespan and stress resistance
increases by pharmacological class, we found that the ability to increase
lifespan and oxidative stress resistance correlated strongly for com-
pounds that target biogenic amine receptors (R2 = 0.61, Fig. 4), but not
for compounds in other pharmacological classes (R2 = 0.18, Fig. 4b).
These findings suggest that some compounds increase lifespan by
mechanisms independent of those involved in oxidative stress resistance,
but that there could be a mechanistic link between oxidative stress
resistance and lifespan extension by compounds that target mammalian
biogenic amine receptors.
The same correlation is also evident in the pharmacological network
(Fig. 5). The ability to induce resistance to oxidative stress is clustered
around biogenic amine receptors, with 24 of 29 compounds that target
these receptors increasing resistance to oxidative stress. Furthermore, 19
of 20 compounds that increase stress resistance by at least 60% are
centered in the biogenic amine receptor network. In contrast, none of
the compounds that target hormone signaling affected oxidative stress
resistance.
Discussion
One long-term aim of aging research is to find drugs that would delay
the onset of age-associated disease in humans. Drug discovery and
development are long and costly processes. However, it is possible that
drugs previously developed for other purposes could prove beneficial for
aging humans without requiring the years of medicinal chemistry and
pharmacological safety profiling needed for the development of a new
drug. C. elegans has homologs of many human proteins and a few
compounds that target human proteins have been found to not only
interact with their nematode counterparts, but also increase C. elegans
lifespan, and in one case, the lifespan of both C. elegans and mice
(Harrison et al., 2009; Robida-Stubbs et al., 2012). Here, we asked
whether it would be possible to identify additional compounds that
increase C. elegans longevity by conducting a large-scale screen of
compounds with known pharmacological targets in mammals. In a
screen of 1280 such compounds, we identified 57 compounds that
increased C. elegans lifespan of which 27 are approved for human use.
These studies provide candidate compounds to explore for helpful
effects on aging in mammals as well as tools to further investigate the
mechanisms underlying aging in C. elegans.
Compounds that increase lifespan in C. elegans
These studies revealed that compounds that target a variety of
mammalian proteins can increase C. elegans lifespan. They newly
identified 56 compounds that increased C. elegans longevity by
5–43% as well as another four compounds previously shown to increase
nematode lifespan (Broue et al., 2007; Petrascheck et al., 2007;
Houtkooper et al., 2013). In the compound library screened, compounds
are divided into 55 pharmacological classes according to the functions of
their target proteins in humans/mice. Compounds that increased
C. elegans lifespan belonged to 15 of those classes.
In these studies, 60/1280 screened compounds increased C. elegans
lifespan, a hit rate of 4.7%. In contrast, when we previously screened
88 000 compounds of undefined function, only 0.13% (115/88 000)
produced a statistically significant increase in C. elegans longevity. One
possible explanation for this difference is that the 1280 compound
LOPAC library comprises compounds with established biological activity
whereas this is not the case for the 88 000 compound library. Consistent
with this idea, examination of data from a different screen of C. elegans
with the LOPAC library also suggests a high hit rate (>3%) (Kwok et al.,
2006). It should also be noted that the LOPAC library contains multiple
compounds that target the same protein or related proteins, another
factor likely to contribute to a high hit rate. Indeed, 29/57 LOPAC
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compounds that increased nematode lifespan in the present studies act
on interrelated biogenic amine receptors in mammals and may similarly
act on the same or interrelated proteins in C. elegans.
The nematode targets of the compounds that increased C. elegans
lifespan in these studies are not yet known. However, the presence of
numerous homologous proteins with similar functions in nematodes and
humans suggests that the compounds may well interact with related
proteins in the two species. Compounds previously shown to interact
with related proteins in nematodes and mammals include several that
target serotonin receptors and a calcium channel blocker (Kwok et al.,
2006; Petrascheck et al., 2007).
The majority of compounds that increased C. elegans lifespan target
mammalian proteins involved in intercellular signaling in mammals
(89%). Many of these compounds [29/57 (50.9%)] act on mammalian G
protein-coupled receptors for biogenic amines (serotonin, dopamine,
adrenaline/noradrenaline, histamine). Most, though not all, are receptor
antagonists. The large number of identified compounds that act on
these receptors may reflect their relatively high abundance in the library
that was screened. C. elegans has GPCRs structurally related to those in
mammals that recognize the same (serotonin, dopamine) or related
(octopamine, tyramine) biogenic amines. Several human serotonin
receptor antagonists were previously found to increase C. elegans
longevity by inhibiting two homologous receptors, one for serotonin and
the other for octopamine, and animals mutant for a different serotonin
receptor also showed increased longevity. Those receptors are potential
targets for some of the compounds identified here that target
mammalian biogenic amine receptors, many of which act on multiple
receptors of this class in mammals (Murakami & Murakami, 2007;
Petrascheck et al., 2007).
The other compounds that increased C. elegans lifespan have a
variety of different mammalian targets. These include several other types
of GPCRs, phosphodiesterases that function downstream of GPCRs,
calcium, and potassium channels, an ionotropic glutamate receptor,
growth factor receptors, protein kinases, proteases, and nuclear
hormone receptors. Interestingly, one compound that increased nem-
atode lifespan (cyclosporin A) binds cyclophilin, causing inhibition of
calcineurin, a protein whose C. elegan’s homolog (CNB-1) is involved in
aging (Dong et al., 2007). Elucidation of the targets of the identified
compounds in C. elegans may provide added information about aging
mechanisms in the animal and contribute to a further understanding of
those mechanisms.
Compounds that increase stress resistance in C. elegans
These studies show that some compounds that increase C. elegans
lifespan also increase the animal’s resistance to oxidative stress, one
stressor proposed to play a role in aging (Harman, 1956). Decreased
insulin/IGF signaling and some DR regimens also increase both lifespan
and oxidative stress resistance in C. elegans (Honda & Honda, 1999;
Houthoofd et al., 2002; Lee et al., 2006). While increased oxidative
stress resistance alone is unlikely to affect lifespan, it might be part of a
constellation of alterations that together allow the animal to live longer
by increasing its ability to repair or prevent damage caused by different
types of stressors.
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Of 57 compounds that increased C. elegans longevity in the present
studies, 33 (57.9%) increased the survival of nematodes exposed to
paraquat, a ROS generator. There was a strong correlation between the
effects of compounds on lifespan and resistance to oxidative stress
(Fig. 4b) for compounds that target biogenic amines, but not for
compounds from other pharmacological classes. The pharmacological
network makes evident that all but seven of the compounds that
increased oxidative stress resistance in C. elegans (26/33) are part of the
biogenic amine receptor network (Fig. 5). Mammalian targets of the
other seven compounds that increased nematode oxidative stress
resistance are phosphodiesterases, proteases, the NMDA type of
glutamate receptor, and the EGF receptor.
These results are consistent with previous observations that some
long-lived C. elegans mutants exhibit increased resistance to oxidative
stress, whereas others do not (Van Raamsdonk & Hekimi, 2009). Many
of the compounds that interact with biogenic amine receptors can bind
to more than one mammalian receptor of this type (Table 1, Fig. 5). By
analogy, if these compounds increase oxidative stress resistance in
nematodes by acting on homologous receptors for biogenic amines, the
observed effects could conceivably be mediated by only one or a few
receptors of this type. One intriguing question for future studies will be
whether compounds that increase stress resistance in nematodes have
similar effects in mammals.
The information obtained in these studies sets the stage for future
studies to investigate whether compounds that increase lifespan in the
nematode may also have a beneficial effect on aging in mammals. Given
the large number of compounds against biogenic amine receptors that
increased nematode lifespan in the present studies, it is intriguing that
an allelic variant of one such receptor, dopamine DRD4, is reported to be
enriched in humans over the age of 90 (Grady et al., 2013).
Experimental procedures
LOPAC1280 library
The library was purchased from Sigma-Aldrich (St. Louis, MO, USA). We
made the following changes to the library annotation. Minocycline was
reassigned from the ‘Cell Cycle’ class to the ‘Antibiotic’ class. All
phosphodiesterase inhibitors were classified as belonging to the ‘Cyclic
Nucleotide’ class, eliminating the ‘phosphodiesterase’ and ‘calcium
signaling’ classes. Quinidine was reassigned from the ‘Na+ Channel’
class to the ‘K+ Channel’ class. All antihistamines were assigned to the
‘biogenic amine/histamine’ class. Compounds in the ‘lipid signaling’ class
were placed in the ‘lipid’ class. The class ‘cytokine and growth factor’
and the class ‘inflammation’ were re-assigned to the ‘immune system’
class. Compounds belonging to the class ‘gene regulation’ were
CytochromeC
30subunit
TUBB2A
CASP−1
EGFR
DAPH
Vincristine
Tyrphostin
AG1478
PDE3
Trequinsin
NR1I2
CDK2
Grm7
MMP9
AMN082
CDK5
ESR2
Minocycline
CASP−2
GNRHR
GNRHR2
CCL2
Danazol
SHBG
ESR1
Kv1.3
LFM−A13
SLC6A3
3,4−DIC**
PDGFR
Proteases
BTCP
Psora−4
BTK
AR
PDEI
Vinpocetine
Eliprodil
Cyproterone
NMDA
SU4312
ALOX5
IL1B
GSK3
Kenpaullone
CDK1
VEGEFR
Demeclocycline
7−Cyclopenty..***
lck
Doxycycline
Nitric oxide
4−Phenyl-3-..*****
(R,R)−THC****
BRL50481
PDE7
Beta−estradiol
Cinnarizine
DRD2
HRH1
Quinidine
DRD5
GABRA1
CACNA1A
KCNH
KCNK1
KCNK6
HRH4
Chlorprothixene
DRD1
Loxapine
DRD3
DRD4
Dihydroergocristine
Propionylpromazine
CHRM2
cis−(Z)−Flupenthixol
Cortexolone
Pergolide
CHRM1
Hexahydro−sila−difenidol
N−(2−[4−(4−Chlorohenyl).. *
CHRM3
CHRM5
CHRM4
ADR2A
ADRA1C
ADRA1B
Doxazosin
ADRA2C
Thioridazine
Nortriptyline
Octoclothepin
SLC6A2
ADRA2B
Amoxapine
Guanabenz
HTR1B
ADRA1D
HTR2B
SLC6A4
HTR2A
HTR1A
BRL15572
LY−165,163 HTR7
HTR3
HTR1D
HTR1FHTR1E
Metergoline
HTR2CHTR6
ABCB1
CACNA1C
Nitrendipine
CyclosporinA
PPIA
CACNG1
CAML
SCN5A
Nicardipine
PPP3R2
ADRA2A Loratadine
Methylergonovine
PromethazineNaftopidil
ADRA1AGuanfacine
LY−367,265
Amperozide
Oxatomide
ALB
Dihydroergotamine
OPRK1
Mianserin
Ketanserin
ABCG2
Serotonin Phosphorylation 
Adrenoceptor Antibiotic 
Hormone Dopamine
Cyclic nucleotideCa2+ Channel 
Other K+ Channel
Fig. 5 Pharmacological network for lifespan extension. Shown is a network generated by connecting compounds (circles) and their respective protein targets (squares).
Arrows indicate agonist action, and T’s indicate antagonist action. For compounds (circles), the node size is proportional to the compound’s effect on lifespan whereas the
size of protein nodes is fixed. Induction of stress resistance is indicated by a red ring around compounds, with the thickness of the ring proportional to the effect magnitude.
Nodes (compounds and targets) and connections between nodes are colored according to pharmacology, as indicated in the key below. See the Fig. 3 legend for names of
compounds that are abbreviated.
Pharmacology of lifespan extension, X. Ye et al. 213
ª 2013 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
re-assigned to the ‘transcription’ class. These reassignments reduced the
original 60 classes to our annotation of 55 classes.
Lifespan assays
The screening procedure was carried out as previously described
(Petrascheck et al., 2007). A detailed protocol is on JoVe (doi: 10.
3791/2496). In short, 5–15, age-synchronized animals were cultured in
S-complete media in wells of 96-well plates containing E. coli OP50 as
feeding bacteria (~2 9 109 bacteria mL1). It should be noted that the
effects of compounds can vary depending upon the assay conditions. For
the screen, each compound was tested at a final concentration of 33 lM
and 0.33%. The concentration used was based on compound and
DMSO concentrations in the library and our finding that >0.5% DMSO
can affect lifespan. Animals were exposed to the compounds continu-
ously beginning on day 1 of adulthood. Controls contained 0.33%
DMSO (vehicle) alone. Screens were conducted blind with the names of
the compounds coded. Living animals were scored by eye. Scoring was
based on movement induced by shaking and application of light to each
well before scoring.
Caenorhabditis elegans stress resistance assays
Animals were cultured in 96-well plates under conditions identical to
those used in the lifespan assays. Compounds were added on day 1 of
adulthood. Five days later (day 5 of adulthood) paraquat (Sigma-Aldrich)
was added to a final concentration of 100 mM. Twenty-four hours after
that, survival was assessed as outlined earlier. Survival was expressed as
the percentage of surviving animals compared with the total starting
population. P values were calculated based on contingency tables and
chi-square analysis and combined with false discovery rates to account
for inflated P values (Gribbon et al., 2005).
Statistical analysis of the lifespan screen
The screen consisted of 1536 populations of animals comprised of four
independent wells each (5–15 animals per well). The lifespan results
were analyzed using two different approaches, which gave nearly
identical outcomes. In the first approach, we used the Cox-proportional
hazard model and calculated FDRs (false discovery rates) as described by
Storey and Tibshirani (Storey & Tibshirani, 2003). In the second
approach, we used the (Mantel–Haenszel) version of the log-rank test.
See supplementary data for details. Generating a Q-Q plot graphing
expected versus observed P-values for each of the four wells of each of
the 250 control populations (DMSO only) showed that the conditions
across the screen were uniform. To determine whether a given
compound extended lifespan, P-values using either the Cox-proportional
hazard model or the Mantel–Haenszel version of the log-rank test were
calculated by comparing compound-treated populations to DMSO-
treated control populations within the same set of plates. Library plates
were tested in quadruplicate; each contained 80 wells that received an
individual compound and eight wells that received only DMSO.
Comparisons were calculated within the same quadruplicates to account
for plate to plate variations. Standard deviations were calculated on the
basis of populations consisting of four wells each.
Statistical analysis of stress resistance in C. elegans
Stress resistance experiments for different compounds were conducted
in parallel. Each compound was tested in four experiments using the
concentration that gave the highest increase in lifespan (Tables S2 and
S3). P values were calculated by comparisons across all four sets of
experiments for the number of live and dead animals when animals were
exposed to a compound versus control vehicle alone. FDR calculations
were conducted as outlined in Storey and Tibshirani (Storey & Tibshirani,
2003). The standard error of the mean, S.E.M., was calculated on the
basis of the number of independent experiments.
Parametric model
Parametric modeling was based on the Gompertz equation. For an exact
description of the derivation of the model, see the Data S1 (Supporting
information).
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